Mirati Therapeutics, Inc. (MRTX)
Current
- (-)
After Hours
Rating Performance
Rating Return
-11.85% vs
Rating Accuracy
0.0% (0 of 1*)
Rating Return
-53.53% vs
Rating Accuracy
0.0% (0 of 1*)
Rating Return
-55.34% vs
Rating Accuracy
33.33% (1 of 3*)
Rating Return
-67.53% vs
Rating Accuracy
50.0% (2 of 4*)
FV Performance
FV Accuracy
0 Hits (0.0% Hit Rate)
FV Avg. Distance
+204.75%
FV Accuracy
0 Hits (0.0% Hit Rate)
FV Avg. Distance
+157.13%
FV Accuracy
0 Hits (0.0% Hit Rate)
FV Avg. Distance
+129.4%
FV Accuracy
15 Hits (30.61% Hit Rate)
FV Avg. Distance
+74.1%
*There is a current rating on the stock that is included in these numbers based on its performance so far
About
CEO
Charles M. Baum
Employees
111
Industry
Oncology Biopharmaceuticals
Sector
Healthcare
Headquarters
San Diego
Exchange
NASDAQ
Website
http://www.mirati.comSummary Stats
Market Cap
3.66B
Revenue
72.8M
Net Income
-634M
EPS
-$11.96
Price-to-Earnings
-5.51
Price-to-Book
2.93
Debt-to-Equity
0.14
News
Analyst Ratings
Price targets projected by 14 analysts
High
$300.00
Average
$235.57
Low
$176.00
Ratings calculated by 15 analysts
Buy
10
Hold
4
Sell
1
Last Dividend
Amount
-
Dividend Date
-
Frequency
-
Dividend Yield
Earnings
Most Recent Earnings
Last Earnings for Q1 2022
Above by $0.09
-$3.40 +2.6%
-3.49
-2.67
Down 27%
Actual vs Estimates
XX
xxx
Upcoming Estimates Unavailable
-
-
-
--